COVID-19 Disease Prevention June 2023: FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the 2023-2024 composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant (ie, XBB.1.5) Mechanism of Action Nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2; formulated in lipid particles, which enable delivery of RNA into host cells to allow expression of the SARS-CoV-2 S antigen Elicits an immune response to the S antigen, which protects against COVID-19 No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print